Vertex Pharmaceuticals News

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 11/10/09, Teva Pharmaceutical Industries Ltd.

Holders of Vertex Pharmaceuticals Inc.'s 2013 convertible senior subordinated notes have agreed to trade about $109 million worth for about 4.8 million shares of Vertex common stock - about 140,000 shares more than the number of shares promised via the notes, the company announced today.

Drug developer Vertex Pharmaceuticals Inc. said Wednesday that holders of $109 million in convertible notes due in 2013 have agreed to swap the notes for about 4.8 million shares of common stock.

Drug developer Vertex Pharmaceuticals Inc. said Wednesday that holders of $109 million in convertible notes due in 2013 have agreed to swap the notes for about 4.8 million shares of common stock.

Vertex Pharmaceuticals' experimental hepatitis C drug telaprevir was the star of last week's big hepatitis C research meeting, according to a well-respected doctor in the field who briefed institutional investors this afternoon.

Vertex Pharmaceuticals Inc. said a study shows its hepatitis C drug telaprevir can be dosed twice per day instead of three times, and Vertex shares shot to their highest price in two years.

Cambridge-based Vertex Pharmaceuticals Inc. is gearing up to highlight its drug to treat hepatitis C as thousands of doctors descend on Boston this week, the Boston Globe reports.

Mapping the human genome produced far more hype than drugs. That's starting to change.

Drug stocks advanced in early trading Monday, as shares of Human Genome Sciences leaped on the release of more positive Phase III clinical data for its new lupus drug Benlysta.

Schering-Plough Corp. said its experimental hepatitis C drug boceprevir helped eliminate the virus in about half of patients who did not respond to standard treatments.

Vertex has announced the results of their Phase 2 Study C208 which explored the use of telaprevir-based regimen in hepatitis C patients.

More than 80% of hepatitis C patients were cured after treatment with a new twice-daily dose of the experimental drug telaprevir made by Vertex Pharmaceuticals , according to data from a phase II study released Saturday.

More than 80 percent of hepatitis C patients in each arm of the Phase 2 Study C208 achieved a sustained viral response with a telaprevir-based regimen according to results of an intent-to-treat analysis announced today by Vertex Pharmaceuticals Incorporated .

SUMMARY: The 60th Annual Meeting of the American Association for the Study of Liver Diseases -- better known as " The Liver Meeting " -- gets underway Friday, October 30, and will run through November 1 at the Hynes Convention Center in Boston.

Vertex Pharmaceuticals Incorporated announced today that treatment with telaprevir-based regimens in Study 107 resulted in high sustained viral response rates in treatment-failure patients infected with hepatitis C virus .

Vertex Pharmaceuticals Inc. said Wednesday its hepatitis C treatment telaprevir created an immune system response to the virus in patients who had not been helped by other drugs.

Vertex Pharmaceuticals Inc. reported a larger third-quarter loss on Monday, as revenue fell and the company spent more money to support the launch of its hepatitis C drug candidate.

Vertex holds first companywide 'day of service' Vertex Pharmaceuticals Inc. encouraged 800 employees to take part in Vertex's first companywide Day of Service, which was held Sept.

Virginia Carnahan, vice president of new product planning and strategy at Vertex Pharmaceuticals, reflects on the industry's changing environment and how to adapt to remain competitive.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.